Review Article
Pharmacological Activities of Safflower Yellow and Its Clinical Applications

Yan Chen 1,2,3, Meifeng Li 1, Jiayu Wen 2, Xiaoli Pan 2, Zixin Deng 2, Junren Chen 1,3, Guanru Chen 1,3, Lei Yu 1,3, Yunli Tang 1,2,4, Gangmin Li 1,3, Xiaofang Xie 1,3, and Cheng Peng 1,3

1 State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu 611137, China
2 School of Public Health, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
3 College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
4 South China Branch of National Engineering Research Center for Manufacturing Technology of Solid Preparation of Traditional Chinese Medicine, Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi 530200, China

CorrespondenceshouldbeaddressedtoXiaofangXie;xiexiaofang@cdutcm.edu.cnandChengPeng;cdtcmpengcheng@126.com

Received 4 March 2022; Accepted 25 May 2022; Published 27 June 2022

Academic Editor: Weicheng Hu

Copyright © 2022 Yan Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Safflower is an annual herb used in traditional Chinese herbal medicine. It consists of the dried flowers of the Compositae plant safflower. It is found in the central inland areas of Asia and is widely cultivated throughout the country. Its resistance to cold weather and droughts and its tolerance and adaptability to salts and alcalis are strong. Safflower has the effect of activating blood circulation, dispersing blood stasis, and relieving pain. A natural pigment named safflower yellow (SY) can be extracted from safflower petals. Chemically, SY is a water-soluble flavonoid and the main active ingredient of safflower. The main chemical constituents, pharmacological properties, and clinical applications of SY are reviewed in this paper, thereby providing a reference for the use of safflower in preventing and treating human diseases.

Methods. The literature published in recent years was reviewed, and the main chemical components of SY were identified based on chemical formula and structure. The pharmacological properties of hydroxysafflor yellow A (HSYA), anhydrosafflor yellow B (AHSYB), and other small-molecule chemicals were reviewed. The main chemical constituents of SY included HSYA, SYA, SYB, and AHSYB. These ingredients have a wide range of pharmacological activities. SY has protective effects on the heart, kidneys, liver, nerves, lungs, and brain. Moreover, its effects include, but are not limited to, improving cardiovascular and cerebrovascular diseases, abirritation, regulating lipids, and treating cancer and diabetic complications. SYA is widely recognised as an effective ingredient to treat cardiovascular and cerebrovascular diseases.

Results. SY has a wide range of pharmacological activities, among which improving cardiovascular and cerebrovascular diseases are the most significant.

1. Introduction
Safflower is native to Central Asia and is a traditional Chinese herb that consists of the dried flowers of the Compositae plant safflower [1]. The Compendium of Materia Medica states that safflower has the effect of “blood circulation, moisturising the skin, analgesic effect, reducing swelling, reducing menstrual bleeding, and improving blood stasis to eliminate edema” [2]. As a traditional medicine, safflower is often used to relieve pain, fight inflammation, and improve micro-circulation in China, the Middle East, and other countries [3].

Safflower yellow (SY) is extracted from safflower petals. It is a water-soluble flavonoid and the main active ingredient of safflower [4]. There are at least 29 compounds in SY (Table 1) [5], and the main compounds include hydroxysafflor yellow A (HSYA), anhydrosafflor yellow B (AHSYB), and other small-molecule chemicals. HSYA,
| No. | CAS number | Ingredients          | Molecular formula | Structural formula |
|-----|------------|----------------------|-------------------|--------------------|
| 1   | 73-24-5    | Adenine              | C$_5$H$_5$N$_5$   | ![Adenine](image)  |
| 2   | 98-79-3    | Pyroglutamic acid    | C$_5$H$_7$NO$_3$  | ![Pyroglutamic acid](image) |
| 3   | 58-61-7    | Adenosine            | C$_{10}$H$_{13}$N$_5$O$_4$ | ![Adenosine](image) |
| 4   | 197227-95-5| Guanosine hydrate    | C$_{10}$H$_{13}$N$_5$O$_5$ | ![Guanosine hydrate](image) |
| 5   | 63-91-2    | Phenylalanine        | C$_9$H$_7$NO$_2$  | ![Phenylalanine](image) |
| 6   | 492-27-3   | Kynurenic acid       | C$_{10}$H$_7$NO$_3$ | ![Kynurenic acid](image) |
| No. | CAS number | Ingredients                        | Molecular formula | Structural formula |
|-----|------------|------------------------------------|-------------------|--------------------|
| 7   | 78281-02-4 | Hydroxysafflor yellow A (HSYA)     | C_{27}H_{32}O_{16} | ![HSYA](image)     |
| 8   | 501-98-4   | p-Coumaric acid                    | C_{9}H_{8}O_{3}   | ![p-Coumaric](image) |
| 9   | 85532-77-0 | Safflor yellow A                   | C_{27}H_{30}O_{15} | ![Safflor](image) |
| 10  | 145134-62-9| 6-Hydroxykaempferol-3,6,7-tri-O-β-glucoside | C_{33}H_{40}O_{22} | ![6-Hydroxykaempferol](image) |
| 11  | 142674-16-6| 6-Hydroxykaempferol-6,7-di-O-β-glucoside | C_{27}H_{30}O_{17} | ![6-Hydroxykaempferol](image) |
| No. | CAS number | Ingredients | Molecular formula | Structural formula |
|-----|------------|-------------|------------------|-------------------|
| 12  | 142674-16-6| 6-Hydroxykaempferol-3,6-di-O-β-glucoside | C_{27}H_{30}O_{17} | ![struct1](image.png) |
| 13  | 145134-63-0| 6-Hydroxykaempferol-3-O-β-rutinoside-6-O-β-D-glucoside | C_{33}H_{40}O_{21} | ![struct2](image.png) |
| 14  | 145134-61-8| 6-Hydroxykaempferol-3-O-β-D-glucoside | C_{25}H_{20}O_{12} | ![struct3](image.png) |
| 15  | 205527-00-0| 6-Hydroxykaempferol-3-O-β-rutinoside | C_{27}H_{30}O_{16} | ![struct4](image.png) |
| 16  | —          | Hydroxycartormin | C_{27}H_{31}NO_{14} | ![struct5](image.png) |
| 17  | 91574-92-4 | Safflor yellow B (SYB) | C_{48}H_{34}O_{27} | ![struct6](image.png) |
| No. | CAS number | Ingredients | Molecular formula | Structural formula |
|-----|------------|-------------|------------------|-------------------|
| 18  | 184840-84-4| Anhydrosafflor yellow B (AHSYB) | $C_{48}H_{52}O_{26}$ | ![Structural formula of Anhydrosafflor yellow B](image) |
| 19  | 29741-09-1 | Apigenin-7-O-$\beta$-glucuronic acid | $C_{21}H_{18}O_{11}$ | ![Structural formula of Apigenin-7-O-$\beta$-glucuronic acid](image) |
| 20  | 79974-25-7 | Cartornin | $C_{27}H_{28}NO_{13}$ | ![Structural formula of Cartornin](image) |
| 21  | 126093-98-9| Safflomin C | $C_{30}H_{30}O_{14}$ | ![Structural formula of Safflomin C](image) |
| 22  | 19895-95-5 | Kaempferol-3-O-$\beta$-sophorose | $C_{27}H_{30}O_{16}$ | ![Structural formula of Kaempferol-3-O-$\beta$-sophorose](image) |
| No. | CAS number | Ingredients                        | Molecular formula | Structural formula |
|-----|------------|-----------------------------------|-------------------|-------------------|
| 23  | 36535-79-2 | Quercetin-3-O-β-rutinoside (Rutin) | C_{27}H_{30}O_{16} | ![Structural formula](image) |
|     |            |                                   |                   |                   |
| 24  | 117-39-5   | Quercetin                         | C_{15}H_{10}O_{7} | ![Structural formula](image) |
|     |            |                                   |                   |                   |
| 25  | 90327-16-5 | Quercetin-3-O-β-glucoside         | C_{21}H_{20}O_{12} | ![Structural formula](image) |
|     |            |                                   |                   |                   |
| 26  | 17650-84-9 | Kaempferol-3-O-β-rutinoside       | C_{27}H_{30}O_{15} | ![Structural formula](image) |
|     |            |                                   |                   |                   |
| 27  | 520-18-3   | Kaempferol                        | C_{15}H_{10}O_{6} | ![Structural formula](image) |
|     |            |                                   |                   |                   |
| 28  | 31159-41-8 | Kaempferol-3-O-β-glucoside        | C_{23}H_{26}O_{11} | ![Structural formula](image) |
|     |            |                                   |                   |                   |
| 29  | 865688-88-6| Quercetin-3-C-β-glucoside         | C_{25}H_{26}O_{11} | ![Structural formula](image) |
especially, plays an important pharmacological role [6, 7]. Messelli et al. [8] isolated HSYA from safflower for the first time. Owing to its abundance and strong biological activity, HSYA is recognised in the Chinese Pharmacopoeia as one of the standard ingredients for the quality control of safflower.

Modern pharmacological studies show that SY has several pharmacological activities, which include but are not limited to improving cardiovascular and cerebrovascular diseases, abirritation [9], regulating lipids [10], and treating cancer [11] and diabetic complications [12]. SY is approved by the Food and Drug Administration of China. Safflower plays an important role in the treatment of cardiovascular and cerebrovascular diseases [13]. The biological activity of SY has been studied conventionally in vitro and in vivo using an experimental mouse model. SY has been reported to have positive effects on the heart, brain, and kidneys of mice. The disease-resistant components of SY and their mechanisms of action are shown in Table 2.

In this study, research progress on the main chemical constituents, pharmacological activities of SY (Figure 1), and its clinical applications (Table 3) were reviewed and summarised, providing a reference for the further development and utilisation of safflower.

2. Pharmacological Activities

2.1. Improving Cardiovascular and Cerebrovascular Diseases (CCVDs). Several in vivo and in vitro studies have shown that SY has significant effects in alleviating CCVDs, including the prevention of atherosclerosis and thrombosis, and as a cardioprotective and neuroprotective. Moreover, the closely related anti-oxidant [39], anti-inflammatory [40], and neuroprotective effects [41] play a role in the prevention and treatment of CCVDs.

2.1.1. Prevention and Treatment of Atherosclerosis. Atherosclerosis is the main cause of cardiovascular and cerebrovascular diseases. This condition mainly occurs in vascular endothelial cells of the large and medium arteries, which are monolayer cells located between plasma and vascular tissues. Endothelial cell injury is considered the basic pathological condition in atherosclerosis. SY is a promising natural product for the treatment of atherosclerosis [42].

Human umbilical vein endothelial cells (HUVECs) are often used as an in vitro model to study the role of endothelial cells. Xie et al. [19] established a hydrogen peroxide (H_{2}O_{2}) induced HUVEC model of oxidative damage and found that HSYA could alleviate the H_{2}O_{2}-induced oxidative damage in HUVECs through upregulating glutathione (GSH) levels, decreasing intracellular reactive oxygen species (ROS) levels, increasing the expression of AKT and Bcl-2 proteins, and inhibiting the expression of Bax and PTEN proteins. The mechanism may be related to the expression of the Bax/Bcl-2 and AKT/PTEN signalling pathways. HSYA significantly upregulates the proliferation rate and down-regulates the mRNA and protein expression of TLR4, MyD88, and nuclear transcription factor-κB (NF-κB) mRNA in a dose-dependent manner in vitro in lipopolysaccharide (LPS) induced endothelial injury in HUVECs and significantly downregulates NF-κB p65 expression [43].

Cui et al. [44] established an H_{2}O_{2}-induced oxidative stress injury model of human vascular endothelial cells EC-304 and found that HSYA could significantly improve the cell survival rate, enhance intracellular superoxide dismutase (SOD) activity, increase intracellular NO levels, and enhance Bcl-2 expression in a dose-dependent manner. It could also reduce the expression of Bax, caspase-3, and cleaved caspase-3. Moreover, HSYA plays a protective role in high glucose-induced vascular injury by inhibiting the generation of H_{2}O_{2} and ROS, activation of NADPH oxidase 4, and the adhesion of adhesion molecules and monocyte endothelial cells [45]. Miao et al. [20] established an oxidised low-density lipoprotein (OX-LDL) induced human coronary artery endothelial cell (HCAEC) model of injury to explore the protective effects of HSYA. The effect was mainly through upregulating the expression of endothelial nitric oxide (NO) synthase (eNOS) gene and protein and increasing NO release. By downregulating the lectin-like low-density lipoprotein receptor 1 (LOX-1) mRNA and protein expression and inhibiting lactate dehydrogenase (LDH) release, HSYA could inhibit the damage induced by high OX-LDL levels in HCAECs, protect cells, and promote cell repair.

HSYA can also affect the adhesion function of vascular endothelial cells, significantly reduce soluble intercellular adhesion molecule (ICAM)-1 and soluble vascular cell adhesion molecule (VCAM)-1 levels in the serum of male Sprague-Dawley (SD) rats, and inhibit the expression of VCAM-1 and ICAM-1 on the surface of the thoracic aorta [46]. The biological mechanism is shown in Figure 2.

2.1.2. Anti-Thrombotic Effects. SY can promote blood circulation and remove blood stasis [40]. Adenosine diphosphate (ADP) is the main component leading to platelet aggregation. SY may affect the expression of activated glycoproteins on platelet membranes by affecting the activation of the downstream conductor of ADP receptors, thereby inhibiting ADP-induced platelet aggregation in humans. The inhibition of platelet aggregation is mainly manifested by the following aspects: ADP receptor transduction and expression of PAC-1 glycoprotein on platelet membranes, calcium ion activation, and regulation of the levels of cyclic adenosine monophosphate, arachidonic acid, and thromboxane (TX) A_{2} in intracellular platelets by ADP [47]. Wang et al. [48] established a phenylhydrazine-induced thrombosis model and verified that HSYA could significantly inhibit thrombosis in vivo and protect the body from exogenous or disease-induced endogenous toxins by promoting blood circulation and accelerating toxin excretion. Studies have investigated the effects of intravenous HSYA injections on the rate of dissolution of blood clots, blood fibrinogen (FIB) levels, prothrombin time (PT), blood coagulation time in experimental animals, and thrombus formation in vivo and in vitro. HSYA has significant thrombolytic effects and can reduce the FIB content to inhibit platelet aggregation and
| Research compounds | Mechanisms | Models | Effect (dose) | Reference(s) |
|--------------------|------------|--------|---------------|--------------|
| HSYA               | ↓ Glutathione (GSH), malondialdehyde (MDA) | Brain injury rats | Anti-cranioencephalomalacia injury (10g/kg) | [14] |
|                    | ↑ SOD activity | H9c2 cell and Sprague-Dawley (SD) rats | Protective effects of hypoxia/reoxygenation on myocardial injury (20μmol/L) | [15] |
|                    | ↓ Cytochrome C, caspase-3, reactive oxygen species (ROS), Mst1/caspase-3 signal pathway | Human umbilical vein endothelial cell (EC-304) | Inhibition of angiogenesis (0.33mg/L) | [16] |
|                    | ↑ Akt and HKII | | | |
|                    | ↑ mRNA expression of p53 gene | | | |
|                    | ↓ mRNA expression of c-myc, VEGF, bFGF, HSPG | | | |
|                    | ↓ mRNA expression of IL-6, IL-10, TNF-α | Septic rats | Anti-inflammatory (120mg/kg) | [17] |
|                    | ↓ CD4⁺CD25⁺FOXP3⁺ Tregs/CD4⁺T lymphocytes | Liver cancer rats | Anti-cancer (1.13mg/kg) | [18] |
|                    | ↓ ROS, BAX, PTEN, TLR4, MyD88, NF-xB mRNA, NF-xB (p65) | Human umbilical vein endothelial cells (HUVECs) | Anti-oxidation (8μg/mL) | [19] |
|                    | ↑ GSH, AKT, SOD, Bcl-2 | | | |
|                    | ↓ LOX-1 mRNA, LDH | Human coronary artery endothelial cells (HCAECs) | Anti-oxidation (0.2mM) | [20] |
|                    | ↑ eNOS, NO | Human bronchial smooth muscle cells (HBSMCs) | Neuroprotective (20μM) | [21] |
|                    | ┤ MAPK/p38/iNOS signal pathway | Coronary heart disease | Anti-inflammatory (40mg/kg) | [22, 23] |
|                    | ↓ Contents of IL-6, TNF-α, IL-1β, MLC phosphorylation, inflammation due to PAF | Male miniature pigs | | |
|                    | ↓ Contents of IL-1β, IL-6, TNF-α, COX-2, iNOS; Bcl-2/Bax ratio | Human gastric adenoma nude rats | Anti-tumour (0.028g/L) | [24] |
|                    | ↑ Phosphorylation of the JAK2/STAT3 pathway | Hyperlipidaemia and fatty liver rats | | |
|                    | ↓ Micro-vessel density (MVD) in BGC-823 tumour tissue | | Regulation of fatty liver (30mg/kg) | [27] |
|                    | ↓ Fatty acid synthetase (FASN), peroxisome proliferator-activated receptor-gamma (PPAR-γ), stearoyl-CoA desaturase1 (SCD1) | Human breast cancer cells (MDA-MB-231) | Anti-tumour (1mg/L) | [28] |
| SYB                | ↑ Matrix metalloproteinase-2 (MMP2) | Acute lung injury rats | | |
|                    | ↑ TNF-α, ICAM-1, IL-1β, IL-6 | Human bone articular chondrocytes | Anti-osteoarthritis (20mg/L) | [29] |
|                    | ↑ TNF-α, IL-6 | Rat chondrocytes | Anti-osteoarthritis (10μM) | [30] |
|                    | ↑ IL-1β, PTGS2, MPP-13 | Ovarian cancer SKOV-3 cells | Anti-tumour (0.25mg/L) | [31] |
|                    | ↑ COL2A1, ACAN | Fenton reaction in vitro | Anti-oxidation (2mmol/L) | [32] |
|                    | ↓ N-cadherin proteins, vimentin proteins, ROS | Human hepatocellular carcinoma cells (HepG2) | Anti-oxidation (150nmol/L) | [33] |
|                    | ↓ E-cadherin protein | | | |
|                    | ↓ 2-deoxyribose oxidation | | | |
|                    | ↓ Nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1), NAD(P)H dehydrogenase | | | |
|                    | ↑ Serum neuron specific enolase (NSE), human S100B (S-100B) | Brain ischemia/reperfusion (I/R) rats | Anti-inflammatory (8mg/kg) | [34] |
| Quercetin          | ↓ ROS, caspase-3 | Steatoarthritis (OA) rats | Anti-inflammatory (8μM) | [35] |
| Kaempferol         | ↑ p-TOR, p-P38K, p-AKT protein | Endometrial cancer cells (MFE-280) | Anti-cancer (10μM) | [36] |
| p-Coumaric acid    | ↓ Blood glucose, creatinine, blood urea nitrogen (BUN), MDA, urine protein (PPO) | Diabetic nephropathy rats | Anti-inflammatory, anti-oxidation (100mg/kg) | [37] |
|                    | ↑ SOD activity | | | |
| Kynurenic acid     | ↑ Heme oxygenase-1 (HO-1) | Human umbilical vascular endothelial cells (HUVECs) | Anti-inflammatory (100μM) | [38] |
prolong clotting time and PT in rats [49]. SYE not only can inhibit thrombosis in the cerebral arterioles of mice but also has a protective effect against haemorrhagic disorders in rats with blood stasis syndrome [5].

HSYA is used in a clinical setting owing to its anti-coagulant effects [50]. The combination of HSYA and low-molecular-weight heparin calcium has a synergistic anti-coagulant effect, which can reduce the incidence of lower limb venous thrombosis [51]. The relevant mechanisms are as follows: (1) SY can antagonise the platelet-activating factor (PAF) receptors and indirectly inhibit platelet aggregation (PAF is an important factor contributing to platelet aggregation, serotonin release, and increasing free Ca$^{2+}$ concentration in platelets) [52]; (2) intravenous injection of SY can reduce the activity of inhibitor plasminogen activator and significantly improve the activity of tissue plasminogen activator in plasma; and (3) SY can combine with hydroxyl free radicals to form HSYA and enhance the ability of endothelial cells to release AT-III, inhibit thrombin activity, and, thus, enhance the anti-thrombosis effect. The biological mechanism is shown in Figure 3.

### Figure 1: The major biological activities of SY.

Myocardial Protection. Myocardial ischemia, occlusion of blood-supplying arteries, and metabolic disorders can lead to myocardial hypoxia. Reperfusion caused by tissue damage is usually aggravating and can lead to...
Table 3: Medicines containing safflower yellow.

| NO. | Product name | Major components | Production enterprise | Function | URL |
|-----|--------------|------------------|-----------------------|----------|-----|
| 1   | The invention relates to a safflower injection rich in HSYA and its preparation | HSYA | Lanzhi Group Wanrong Pharmaceutical Co. Ltd. | Promote blood circulation and remove blood stasis, increase coronary flow and myocardial nutrient blood flow, effectively dilate blood vessels, inhibit thrombosis and platelet aggregation, and reduces inflammation | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 2   | The use of HSYA during the preparation of health drugs or functional foods for the treatment of hypoxic pulmonary hypertension | HSYA | Harbin Medical University | Prevent and treat pulmonary hypertension | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 3   | A drug composition for the treatment of kidney diseases and its pharmaceutical use | Rhubarb acid, emodin methyl ether, emodin glycoside, rhubarb glycoside, danshensu, salvianolic acid B, HSYA, astragaloside iv, astragalus polysaccharide, salvianolic acid A, and mullein isoflavone glycoside | Xi’ An Cntury Shengkang Pharmaceutical Co. Ltd. | For the treatment of kidney disease, renal failure, nephrotic syndrome, cardiovascular and cerebrovascular diseases, and tumours | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 4   | Application of safflower yellow during the preparation of drugs for treatment and/or prevention of acute soft tissue injury | Safflower yellow | Beijing Institute of Cardiopulmonary and Vascular Diseases | Treat and/or prevent acute soft tissue injury caused by inflammatory factors | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 5   | Compound combinations, with peach red siwu soup as the source | Peach kernel, safflower (safflower yellow), angelica sinensis, rehmannia glutinosa, white peony root, and six chuanxiong herbs | Jinan University | Prevent and cure cardiovascular diseases | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 6   | Application and dehydration of safflower yellow B during the manufacture of gastric cancer drugs | AHSYB | Binzhou Medical College | As an ERK regulator to cell cycle to inhibit gastric cancer cell proliferation | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 7   | The utility model related to a drug composition for the treatment of cardiovascular and cerebrovascular diseases | Salvianolic acid B and HSYA were the main active components | Chengdu Purifa Drug Development Co. Ltd. | Prevent or treat cardiovascular and cerebrovascular diseases | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 8   | Application of HSYA during the preparation of drugs for treating sepsis | HSYA | Tianjin Chase Sun Pharmaceutical Co. Ltd. | Treat sepsis | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
### Table 3: Continued.

| NO. | Product name | Major components | Production enterprise | Function | URL |
|-----|--------------|------------------|-----------------------|----------|-----|
| 9   | The invention relates to the procyanidin safflower yellow compound soft capsule and its preparation | These include safflower seed oil, procyanidins, safflower yellow, sodium alginate, and Tween-80 | Urumqi Shangshanyuan Biotechnology Co. Ltd. | Prevent or treat cardiovascular and cerebrovascular diseases; improve memory, slow aging, prevent stroke, promote cholesterol decomposition, moisturise the skin, and maintain health | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 10  | The invention relates to shujinhuoxue capsules and their preparation | Safflower (safflower yellow), rhizoma corydalis (made), dog ridge (made), xiangjia skin, mistletoe, zealanthus leaves, xiejin grass, luoshu rattan, caulis spatholobus, natural copper (forged), and ten kinds of single medicines | Hangzhou East China Pharmaceutical Group Kangrun Pharmaceutical Co. Ltd. | Relax tendons | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 11  | The invention relates to a fingerprint of shujinhuoxue preparation and its application in overall quality evaluation | It uses *Panax notoginseng*, peach kernel, bone scissora, safflower (safflower yellow), angelica sinensis, maca, and licorice as raw materials | Zhejiang University of Technology | Improve micro-circulation in bone; promote oxygen, calcium, and other nutrients to enter the bone; and encourage bone metabolism to return to normal, so as to effectively improve osteoporosis | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 12  | The invention relates to a natural composition that can improve the disturbance of blood micro-circulation and osteoporosis and the preparation method | Type II collagen, turmeric, active protectant, and colourant (safflower yellow) | Ezhou Institute of Industrial Technology, Huazhong University of Science and Technology; Huazhong University of Science and Technology | Inhibit the proliferation of breast cancer cells | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 13  | Application of dehydrated safflower yellow B during the preparation of breast cancer drugs | AHSYB | Binzhou Medical College | Inhibit the proliferation of breast cancer cells | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 14  | The invention relates to a composition containing type II collagen and a preparation process thereof | Danshen extract, chuanxiong extract, matrine extract, gallnut extract, safflower extract (safflower yellow), brucea javanica extract, and excipients | Beijing Suwei Biological Technology Co. Ltd. | Inhibit inflammatory response, improve the role of arthritis, and assist collagen treatment of inflammatory diseases | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 15  | The invention relates to a traditional Chinese medicine composition for treating scars and its preparation and application | Guizhou University of Traditional Chinese Medicine | Cure scars | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
| 16  | Application of HSYA in the preparation of tinnitus drugs and drug boxes | HSYA | Binzhou Medical College | Treat anxiety and depression caused by tinnitus | https://pss-system.cnipa.gov.cn/sipopublicsearch/patentsearch/showViewList-jumpToView.shtml |
Figure 2: The mechanism of HSYA protecting and repairing endothelial cell injury.

Figure 3: The mechanism of HSYA inhibiting platelet aggregation.
myocardial ischemia/reperfusion (I/R) injury. Myocardial I/R injury poses a serious threat to human health and is one of the important risk factors for myocardial infarction (MI) associated with several complex pathological changes.

SY shows potential in treating myocardial I/R and might protect from myocardial ischemia by reducing myocardial oxygen consumption. It could improve the ability of normal rats to resist hypoxia at normal pressure and prolong the survival time of rats under hypoxia, suggesting the effectiveness of SY pigment [53]. Studies have reported that the expression of the anti-apoptotic protein Bcl-2 decreased and that of the proapoptotic protein Bax increased in hypoxia/reoxygenation (A/R) injured primary myocardial cells of suckling rats, whereas these trends were reversed after HSYA treatment. The anti-apoptotic effect of HSYA is lost after the addition of the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002, which indicates that HSYA can reduce apoptosis in A/R-injured myocardial cells by activating the PI3K pathway [54]. HSYA can also protect the cardiomyocytes of rats from A/R injury by regulating the phosphatidylinositol-3-kinase/protein kinase B/glycogen synthase kinase 3β (PI3K/Akt/GSK3β) signalling pathway.

HSYA can reduce serum angiotensin II (Ang II), TXB₂, and LDH levels in the cardiovascular system and protect endothelial cells and preserve myocardial systolic function. These findings indicate that HSYA provides cardiac protection by increasing myocardial blood flow and oxygen supply to effectively alleviate heart disease caused by myocardial ischemia and other ischemic factors [55].

In both the mouse model of MI and the SD rat model of I/R, HSYA can reduce the area of MI and alleviate the deterioration in cardiac function after MI to varying degrees, specifically by reducing myocardial cell apoptosis and myocardial fibrosis [56, 57]. In addition, HSYA can improve autophagy and inhibit the NLRP3 inflammasome [58] by inhibiting the mTOR pathway and activating AMPK.

2.1.4. Brain Protection. HSYA is widely used to treat cerebrovascular diseases and in the protective treatment of I/R injury [59]. The proteomic analysis reported by Xu et al. [60] showed that the mTOR, Eftud2, Rab11, Ppp2r5e, and HIF-1 signalling pathways are key central proteins and important pathways of HSYA in preventing cerebral I/R injury. HSYA can reduce cerebral infarction volume; decrease the neurological deficit score; increase GSK3β phosphorylation; inhibit the activation of iNOS, NF-κB, and caspase-3; and decrease iNOS, NF-κB, and caspase-3 activity in the penumbra after cerebral I/R. HSYA exerts an anti-inflammatory and anti-apoptotic effect by regulating GSK-3β phosphorylation, thereby reducing I/R injury [61]. Cao et al. [62] established in vitro oxygen-glucose deprivation (OGD) model using brain micro-vascular endothelial cells (BMECs) and evaluated the protective effects of astragaloside IV (AS-IV) and HSYA. Their results showed that AS-IV and HSYA significantly attenuated OGD-induced cell loss by increasing cell proliferation and inhibiting apoptosis, and HSYA treatment protected bone marrow mesenchymal stem cells from IR injury by stimulating vascular endothelial growth factor and NOS signalling. AS-IV and HSYA show synergistic effects in the in vitro rescue of BMECs by down-regulating PHLPP-1 expression and activating the Akt signalling pathway. HSYA combined with the blood-brain barrier (BBB) modulator Lex can significantly reduce the volume of cerebral infarction, improve histopathological morphology, recruit brain-derived neurotrophic factors, and alleviate cerebral I/R injury [21].

The neuroprotective effect of HSYA on focal cerebral ischemia is mainly achieved by regulating the crossstalk between Janus kinase (JAK) 2/signal transducer and activator of transcription (STAT) 3 and the suppressors of cytokine signalling (SOCS) 3 pathway. Its effect can be speculated as follows: HSYA may inhibit JAK2-mediated signal transduction, further activate p-JAK2/p-STAT3 expression, and then stimulate the downstream activation of SOCS3, resulting in the negative feedback signal by SOCS3 to p-JAK2/p-STAT3. It is also possible that HSYA can directly activate SOCS3, thereby neutralising JAK2/STAT3 activation, which is detrimental [63]. HSYA can down-regulate the expression of cytokines, including NLRP3, ASC, caspase-1, gasdermin D, interleukin (IL)-1β, IL-18, LDH, NF-κB, and p-p56, suggesting its inhibition of the activation of cellular apoptosis and autophagic pathways during nerve injury [21].

HSYA can enhance the expression of epidermal growth factor receptor, hypoxia-inducible factor 1α, and eNOS and promote angiogenesis [64]. Among them, eNOS activation can alleviate neurovascular injury and improve functional prognosis after a stroke, and HSYA can upregulate eNOS levels [65]. HSYA can reduce malondialdehyde levels and increase glutathione and SOD levels to inhibit ROS and can also activate Akt and β-catenin signals to promote nerve cell survival [66].

2.1.5. Anti-Oxidant Effects. SY exerts significant anti-oxidant effects by removing hydroxyl free radicals and inhibiting lipid peroxidation [67]. HSYA and SYB are the two major active substances in SY that contribute to this effect. HSYA can directly remove hydroxyl free radicals in a dose-dependent manner, whereas SYB inhibits Fenton’s oxidative damage to 2-deoxyribose. The anti-oxidant effects of both these components are potent [37, 68–70].

SOD level decreases in lens epithelial cells undergoing oxidative damage. HSYA can significantly increase SOD levels to protect against lens epithelial cell damage [71]. Similarly, HSYA can increase the activities of SOD and catalase in brain-injured rats with trauma and can also reduce malondialdehyde and glutathione levels in acute ischemic stroke [72].

HSYA can reduce the expression of the metabolite 15-hydroxyecosatetraenoic acid (HETE) in a dose-dependent manner and reduce the breakdown of the BBB, indicating its role in reducing oxidative stress, inhibiting 12/15-lipoxygenase activity, and protecting the relative integrity, structure, and function of the BBB, thereby exerting a brain-
2.1.6. Anti-Inflammatory Effects. SY has an anti-inflammatory effect [79, 80]. It can downregulate the expression of toll-like receptor 4 (TLR4) and NF-κB p65 proteins in myocardial tissue of rats after myocardial I/R injury and significantly reduce serum tumour necrosis factor α (TNF-α) and IL-6 levels, indicating that SY plays an effective inhibitory role in affecting the inflammatory response to myocardial I/R injury in rats. Its mechanism might be related to regulating the TLR-NF-κB pathway [81, 82]. Besides, the anti-inflammatory mechanism of SY might also be related to the inhibition of the MAPK pathway. It has been reported that SY injection can inhibit p38 MAPK phosphorylation and NF-κB activation in a dose-dependent manner, resulting in a reduction in the levels of TNF-α, IL-1β, IL-6, ICAM-1, VCAM-1, and adhesion molecules in a rat model of oleic acid-induced acute lung injury [83, 84].

HSYA can improve airway function and relieve inflammation in patients with bronchial asthma by inhibiting immunoglobulin E and platelet-activating factor (PAF) levels, rebalancing T helper 1 (Th1)/Th2 cells, and blocking the MAPK signalling pathway. These findings suggest that HSYA plays a multifunctional role in the prevention and treatment of asthma. Due to the multitarget characteristics of HSYA and its few side effects, it is being used in the research and development of new anti-asthma drugs [85].

IL-10 is an anti-inflammatory factor that can inhibit the synthesis and secretion of proinflammatory factors during an inflammatory response. However, excessive IL-10 can cause nonspecific immune disorders in the body. SY pigment can inhibit the excessive increase in IL-10 and reduce TNF-α and IL-6 levels to reduce inflammation due to viper bite poisoning [86]. In summary, HSYA can inhibit signal transduction and the expression of inflammatory factors to reduce the inflammatory response; moreover, it has a certain anti-inflammatory effect.

2.2. Abirritation. HSYA has a strong analgesic effect that might be related to the inhibition of the MAPK/p38/iNOS pathway and NO release. HSYA can significantly reduce writhing in rats following treatment with acetic acid and can also increase their pain threshold (pain induced by a hot plate) in a dose-dependent manner. HSYA can significantly reduce the NO content of LPS-induced macrophage RAW264.7 cells by inhibiting the MAPK/p38/iNOS signalling pathway [26].

HSYA injections have been recently reported to be effective as an adjuvant drug in the management of angina pectoris [9, 87, 88]. The proposed mechanisms of action include regulating the intracellular flow of Ca²⁺, promoting blood circulation, vasodilation, and increasing blood supply for tissue and organs. High blood viscosity can cause angina pectoris. Fortunately, the SY pigment can release prostacyclin by activating vascular endothelial cells and increasing coronary blood flow [89, 90]. These reported findings indicate that HSYA can activate vascular endothelial cells to release prostaglandins by inhibiting the MAPK/P38/iNOS pathway, thus resulting in an analgesic effect.

2.3. Lipid Regulation. SY can lower blood lipids [91, 92]. Intravenous injections of SY can significantly reduce serum low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and total cholesterol (TC) levels in rats with hyperlipidaemia and increase high-density lipoprotein cholesterol levels [49].

HSYA can also improve the pathological morphology of organs caused by hyperlipidaemia. The liver plays an important role in lipid metabolism and the synthesis of endogenous cholesterol. Dyslipidaemia can easily increase the burden on the liver leading to hepatic dysfunction. Chai et al. established a fatty liver model of hyperlipidaemia in rats [93]; when treated with HSYA, the lipid droplets in liver cells reduced remarkably in a dose-dependent manner.

Li et al. found that HSYA could significantly reduce the mRNA expression of fatty acid synthase, peroxisome proliferator-activated receptor (PPAR-γ), and stearoyl-coa-desaturase in liver tissues. Silent information regulator 1 (Sirt1) is a histone deacetylase that can regulate gene expression by regulating gene transcription. Sirt1 can inhibit the expression and activity of PPAR-γ and downregulate the expression of fat storage-related genes. HSYA can protect the liver by affecting Sirt1 to regulate the high fat-induced lipid accumulation in the liver [34]. HSYA can regulate receptor expression and lower LDL levels, thereby lowering blood lipid levels.

Yin et al. administered intramuscular vitamin D3 injections and nicotine gavage to establish a rat model of atherosclerosis. They found that HSYA could reduce serum lipid levels, but it was not better than the classic lipid-lowering drug simvastatin at a human equivalent dose [92, 94]. Therefore, HSYA can be used as an adjuvant in lipid-lowering therapy [95].

2.4. Anti-Cancer Effects. Within a certain dose range, HSYA can inhibit several carcinogens by inhibiting tumour neovascularisation, also inhibit the growth of several types of tumour cells, and induce tumour cell apoptosis [96].

Tumour angiogenesis is an important factor leading to tumour growth, invasion, and metastasis [97]. It has been reported that 28 mg/L of HSYA can effectively inhibit the growth of transplanted tumour tissues in rats, indicating that HSYA has an inhibitory effect on tumour angiogenesis [98].

MDA-MB-231 is a malignant, invasive, triple-negative breast cancer cell line that is resistant to certain
chemotherapy drugs [99]. MDA-MB-231 is the ideal in vitro model to study drugs used to treat breast cancer [100]. HSYA can inhibit the metastasis-related protein matrix metalloproteinase 2 (MMP2) in MDA-MB-231 cells to inhibit the migration and invasion of breast cancer cells and promote apoptosis of breast cancer cells by activating the caspase-3-dependent apoptosis pathway [35]. In addition, studies have been performed to screen the in vitro activity of SY by using time- and dose-dependent cell response spectra induced by epidermal growth factor (EGF) and to evaluate the anti-metastasis effect of SY by orthotopic pulmonary metastasis and intravenous injection. The results show that SY inhibits the EGF-mediated time and dose-dependent cell response spectra by inhibiting cytoskeletal rearrangement. Moreover, SY has significant inhibitory effects on cell migration in vitro and lung metastasis of breast cancer cells in vivo. Consistent with these phenomena, in SY-treated MDA-MB-231 cells and in lung metastases, EGF stimulation reduces invasion-site formation and MMP-9 and P-SRC protein expression. These data suggest that the anti-metastasis effect of SY is due to its inhibition of invasive cytoskeleton formation, which is mainly mediated by P-SRC protein [101]. In conclusion, SY can inhibit MMP2, caspase-3, and P-SRC in MDA-MB-231 cells to inhibit breast cancer and exert an anti-metastatic effect.

Ovarian cancer has the highest mortality rate among gynaecological malignancies. Cisplatin-based chemotherapy is the basic postoperative treatment [102]. Multiple studies have reported that protein kinase B (PKB, also known as Akt) activators can promote chemo-resistance and increase the survival of ovarian cancer cells by attenuating the p53 pro-apoptotic signal [103]. Yang et al. found that phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) has a significant effect on cisplatin resistance in human epithelial ovarian cancer, and the inhibition of the PI3K/AKT pathway can significantly increase the sensitivity of tumour cells to cisplatin [104]. Liang et al. transplanted the cisplatin-resistant human ovarian cancer cell line A2780/DDP into nude rats to study drug intervention and found that HSYA enhanced the sensitivity of A2780/DDP to cisplatin by downregulating the PI3K/AKT pathway and inhibiting the p-AKT protein [105]. The results suggest that HSYA can reduce drug resistance in ovarian cancer.

Earlier, Wang et al. applied HSYA directly to BG C823 human gastric cancer cells and found that it significantly inhibited the proliferation of BG C823 cells after 48 h [106].

2.5. Treatment of Diabetic Complications. Diabetic nephropathy (DN) is one of the major micro-vascular complications of diabetes mellitus (DM) disability and death [12, 107]. SY can prolong PT. HSYA is a platelet-activating factor receptor antagonist that can decrease 5-hydroxytryptophan and free Ca²⁺ concentration in platelets and cause platelet adhesion. As a result, HSYA can reduce blood glucose levels, blood viscosity, and homeostasis model assessment in patients with early type 2 DN to relieve renal damage and improve insulin resistance [108].

In DM, long-term high glucose levels can induce excessive ROS leading to apoptosis and functional damage to islet β cells. In such cases, HSYA can reduce excessive ROS production by inhibiting the JNK/c-jun signalling pathway, thereby significantly protecting β cells and islet function [109].

3. Pharmacokinetic Studies

HSYA is a representative chemical compound of the bio-pharmaceutics classification system class III drugs. Pharmacokinetic studies show that HSYA has high water solubility but poor intestinal membrane permeability, resulting in low oral bioavailability of only 1.2%, of which 48% of the prototype drug is excreted in the urine, 2.9% in faeces, and only 0.062% ± 0.011% in the bile. Similarly, 88.6% was directly excreted in the urine after intravenous administration [40, 110]. In addition, owing to its polarity and solubility, HSYA is easily degraded and metabolised in the liver and gastrointestinal tract, leading to malabsorption. Moreover, it is eliminated quickly and has a very short half-life [111]. Safflower oral solution and SY injection are HSYA-containing preparations currently used in clinical practice [112]. Disease status can affect the metabolism of SY pigments in the body. Yao et al. [113] first reported the pharmacokinetic differences in HSYA between normal mice and streptozotocin-induced mice with diabetes. In the DCM group, mice exhibited a significantly higher area under the curve (AUC0-t and AUC0-∞) and peak plasma concentration for HSYA than those in the normal group, suggesting a high uptake of HSYA by mice in the DCM group. Furthermore, the plasma clearance and apparent volume of distribution were significantly lower in mice in the DCM group than those in the HSYA-treated group, indicating slower elimination in the DCM group than in the normal group. These results indicated significant changes in HSYA pharmacokinetics in mice with diseases.

HSYA is distributed in the heart, liver, spleen, lungs, kidneys, brain, and gastrointestinal tract of rats after the oral administration of safflower water extract and SY pigment, but the content was higher only in the gastrointestinal tract and lungs [114]. After intravenous safflower injection, the AUC of HSYA in different organs was in the order of blood, kidneys, liver, lungs, heart, and spleen but was not detected in the brain, possibly because HSYA could not easily cross the BBB [115]. However, relevant studies have shown upon injection; HSYA can enter the brain of rats with traumatic brain injury and play a protective role in the nervous system [72].

Jin et al. [116] first conducted a comparative study between the metabolism in normal rats and in those with blood stasis syndrome after the intragastric administration of HSYA. In addition to the prototype drug, eight related metabolites were detected in normal rats, including five phase I metabolites (hydrolysis, reduction, hydroxylation, hydration, and methylation) and three phase II metabolites (acetylation, glucinal acidification, and glucinal acidification plus hydroxylation). However, only seven metabolites
were detected in rats with blood stasis syndrome, and no glucose aldehyde acidification and hydroxylation products were detected, indicating that the metabolites of HSYA differed among animal models. Moreover, the hydroxylated, hydroxylated plus methylated, acetylated, and glucose aldehyde-acidified metabolites were higher among other metabolites, suggesting their role in the pharmacological activity of HSYA [117].

Besides, related research has found that after rats were administered safflower water extract and SY pigment, the cumulative excretion rate of HSYA was the highest, followed by that in the urine, and the least in the bile. HSYA is mainly excreted in the urine during intravenous administration [114]. However, Jia et al. [118] found that when rats were intravenously administered Xuebijing injection, the urine: faeces drug-excretion ratio reached the maximum value 8–12 h after administration; approximately 50% of HSYA was detected in the stools and 3.41% in the urine after 25 h, suggesting that HSYA was mainly excreted from stools after intravenous administration, which may be related to other components in Xuebixin.

4. Clinical Applications of SY Pigment

SY is a valuable natural pigment and the main active ingredient of safflower. SY has multiple positive traits, including its bright colour; resistance to high and low temperature, high pressure, light, acid, and reducing agent; and anti-microbial properties. SY has long been used in a clinical setting.

In China, safflower has long been used as an important herbal medicine, with the first known record in the Song Dynasty in “Kai Bao Ben Cao.” Safflower has been cultivated for more than 2,000 years. It has the effects of activating blood to regulate menstruation and resolving blood stasis to relieve pain. It is compatible with other drugs traditionally used to treat amenorrhea, menorrhagia, lochia, stasis, masses in the body, chest pain, abdominal pain, trauma and fracture, swelling, and ulcers on the body surface. Safflower is currently used both internally and externally to treat gynaecological and obstetrical conditions, cardiovascular and cerebrovascular diseases, trauma, and fractures (Table 3) [119, 120].

The chemical constituents of safflower are complex and include flavonoids, steroids, phenolic acids, diols, lignans, chalcone, alkalines, and volatile oils. Among them, SY is the major active ingredient. HSYA is the key active ingredient in SY. Therefore, HSYA is usually used as an indicator for the quality control of SY as described in pharmacopoeia [121]. Owing to their diverse pharmacological effects, low costs, and other advantageous traits, herbal compounds are increasingly attracting the attention of scientists worldwide [122]. AHSYB, the second-most prominent ingredient in SY after HSYA, contains phenolic hydroxyl groups that are responsible for its anti-oxidant effect. AHSYB has a good dyeing effect, making it a useful colouring agent for tablets and in preparing sugar coatings [123].

Safflower is used in traditional Chinese medicine for promoting blood circulation and removing blood stasis. It has a definite curative effect on cardiovascular and cerebrovascular diseases and has broad application prospects. HSYA can be used as a vascular relaxant and shows potential in the treatment of cardiovascular diseases [124]. TRPV4 is related to vascular tension. Yang et al. [124] found that HSYA can increase Ca2+ levels in endothelial cells through the TRPV4 channel and activate eNOS and its phosphorylation through protein kinase A, thus promoting NO production and leading to vascular relaxation. HSYA causes vasodilation mainly by the activation of the BKCa channel, inhibition of the L-type calcium channel, and reduction of intracellular free Ca2+ levels [125]. As a Chinese herbal medicine, SY, the main active ingredient, can be used in the treatment of myocardial I/R injury. Using in vivo and in vitro models, Lu et al. [4] studied whether SY could reduce myocardial I/R in rats and provided the theoretical basis for its use as a potential drug to treat myocardial I/R injury. In vivo experiments show that safflower can improve cardiac function after myocardial I/R injury and effectively attenuate I/R-induced MI. N-acetylcysteine can be used to remove ROS in an in vivo I/R model, or a preinjection of SY into the internal jugular vein of rats can reduce the expression of the inflammatory cytokines IL-6 and TNF-α, especially IL-1β. An in vitro myocardial model shows that SY reduces I/R injury by inhibiting the release of LDH and reactive ROS. In vitro studies have further verified and explained the potential mechanism of its cardioprotective effects. In addition, SY pretreatment significantly reduced I/R-induced NLRP3 expression and caspase-1 activation. In summary, these results suggest that SY intervention before reperfusion can reduce myocardial I/R injury. However, the protective mechanism of SY in myocardial I/R injury needs further study and experimental analysis.

In 2017, the World Health Organization reported that chronic obstructive pulmonary disease (COPD) was the third-most common cause of death among the top 10 causes, accounting for about 5% of all deaths [126]. The current treatment regimen for acute exacerbation of COPD (AECOPD) can only bring about a change in patients from the acute exacerbation phase to the stable phase; however, this condition cannot be completely cured. Traditional Chinese medicines exert a unique therapeutic effect. Li et al. [7] conducted a randomised controlled trial to determine the clinical efficacy of SY to treat AECOPD. Their experimental results show the PAF receptor as a potential target for the treatment of AECOPD. SY injection can alleviate pulmonary hypertension in patients with AECOPD, effectively alleviate right ventricular failure, and alleviate myocardial ischemia and reduce WOB to some extent. SY intervention can significantly shorten the average length of stay of patients (P = 0.006), reduce the average hospitalisation costs, and shorten the time of mechanical ventilation. Meanwhile, the use of SY instead of other drugs to treat AECOPD saves limited medical resources and is associated with good medical benefits and social welfare. However, their study has some limitations such as the limited representation of clinical samples. With respect to scientific research methods and sample inclusion, there is an obvious gap bridging multicentre, large sample, and triple-blind trials. There is
also a gap with respect to international standards in medical technology and examination methods. Due to these limitations, no samples were collected for cytology or molecular biology studies. Thus, the effective molecular mechanism of SY in the treatment of AECOPD could not be determined. To summarise, researchers worldwide should focus on performing more randomised controlled trials to further evaluate the clinical value of SY.

Hepatocellular carcinoma (HCC) is a malignant tumour associated with a high rate of mortality worldwide that poses a serious threat to human life and health [127]. Chemotherapeutic drugs such as cisplatin inhibit DNA replication and damage cell membranes and are widely used to treat cancer; however, their side effects limit their use. Previous studies have shown that Chinese medicines, including Chinese herbal medicines such as safflower, lead to an enhancement of the anti-tumour effect when combined with cisplatin [128, 129]. Ma et al. [11] used the combination of cisplatin and HSYA in a mouse model of liver cancer and specifically studied the anti-tumour effect of HSYA on HCC and its impact on the tumour immune micro-environment. The study found that after HSYA therapy, the tumour cells decreased significantly. Optimal tumour growth-inhibiting effect was obtained at a concentration of 1.13 mg/kg HSYA. In a study in Central Asia, HSYA was found to lower the expression of Foxp3 and Rorgt in tumour tissue in the spleen, enhance immunity in mice, and reduce liver tissue damage due to cisplatin chemotherapy, thereby regulating the tumour immune micro-environment and exerting an anti-cancer effect. However, the immune micro-environment of the body is complex and involves several immune factors. The aforementioned study lacks systematicity and comprehensiveness. Moreover, the influence of HSYA on other important immune factors needs further elucidation.

DN is a serious complication resulting from changes in the renal structure and function in patients with diabetes. The incidence of DN is increasing and is the main cause of death in patients with diabetes [130]. Wang and a few others were not multicentre, large-sample, high-quality clinical trials; thus, the clinical safety and efficacy of SY are yet to be established. Although previous studies have reported SY to be effective in the treatment of DN, its side effects are unclear. Additional rigorous studies and in-depth experimental design are required to determine the role of the drug in treating DN. Thus, future studies should focus on establishing comprehensive and effective schemes for the standardisation of randomised controlled trials.

SY and sodium chloride injection is a newly reported combination that has the effect of activating blood and blood and pain. The combination of metoprolol and SY injection has been reported to be effective in treating unstable coronary heart disease or angina pectoris by increasing serum TC, TG, and LDL-C levels and alleviating the symptoms of these conditions [136–140]. Wang et al. [141, 142] found that the Chinese patent Taohong Siwu keli (granules) significantly inhibited platelet aggregation when administered to SD rats with thrombotic cardiovascular and cerebrovascular diseases. Bitong Keli (Granule), processed and refined from 18 traditional Chinese medicines (including safflower, Pueraria radix, and bougainvillea), is formulated according to the basic theory and experience of traditional Chinese medicine. Owing to its definitive curative effect, Bitong Keli has long been used in clinical practice. Clinically, Bitong Keli is mainly used to treat cervical spondylitis, radicular pain, limb numbness, and restricted limb movement [143, 144]. Chitosan (CS) micro-spheres have been recently reported as a new pharmaceutical delivery system. CS can be used to achieve long-term effects by regulating the drug-release rate and protecting it from enzymatic degradation. This new technology has been used to synthesise slow-release HSYA-CS micro-spheres, which greatly reduce the number of medications, extend drug activity, and improve drug efficacy after injection. HSYA-CS can be prescribed at a lower dose and is more efficacious compared with traditional HSYA formulations [145].

5. Discussion

Although multiple pharmacological effects of SY have been reported, it continues to be a popular research field. One of the important reasons is that the new therapeutic effects that are being discovered by combining HSYA with other active components of traditional Chinese medicine show broad application prospects, and the mechanisms of action warrant elucidation at multiple levels. Other components of safflower are known to have extensive physiological activities and are of great value for further research. The complete research and development of safflower resources will be significant in guiding clinical practice and new drug development.

The application of SY in the medical field is extensive. SY has high stability and several pharmacological activities; however, its effects may be altered by light or exposure to the sun. Although several studies exist on the pharmacological activities of SY in recent years, some are relatively superficial and unsuitable to be used as a theoretical basis for further experimental research to promote the research and development of relevant drugs. This is one of the factors limiting the medicinal value of SY. As mentioned earlier, no samples were collected for cytology or molecular biology studies;
thus, the effective molecular mechanism of SY in the treatment of AECOPD could not be determined. The protective mechanism of SY on myocardial I/R injury needs further study and experimental analysis. Some studies on SY lack systematicity and comprehensiveness. The clinical safety and efficacy are limited and the side effects of SY during the treatment of DN are still unclear.

Drugs can be developed according to clinical needs. The active components of SY can be extracted and separated, and their structures can be optimised to synthesise relevant drugs. SY exerts its effects by a combination of multiple pharmacological functions. It can be used alone and also combined with Western medicine to treat related diseases. Its toxicity is lower than that of most drugs. Future studies should be focused on the collaboration of domestic and foreign pharmaceutical researchers to conduct randomised controlled trials for an in-depth study on the mechanisms of action of the active ingredients of SY. This would enable more comprehensive and effective standardised treatment schemes to be introduced, help identify side effects, and shed light on drug safety, clinical applications, and precise specifications, thereby highlighting the clinical value of SY in promoting drug research and development and benefitting the society at large.

6. Conclusions

SY is a natural yellow pigment extracted from safflower petals. The major active substances of SY are water-soluble flavonoids. SY has multiple pharmacological activities, including alleviating cardiovascular and cerebrovascular diseases and abirrination. Moreover, it is known to have anti-cancer effects and is reported to be useful in treating diabetic complications. Therefore, SY is widely used in a clinical setting. Further research on the compatibility, stability, and thermal instability of SY is warranted. Compatibility and stability are crucial factors governing medicinal use. Thus, in-depth studies on the thermal instability of SY are significant prior to the development of SY-containing products.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| SY           | Safflower yellow |
| HSYA         | Hydroxysafflor yellow A |
| HSYB         | Hydroxyl safflower yellow pigment B |
| AHSYB        | Anhydrosafflor yellow B |
| CCVDs        | Cardiovascular and cerebrovascular diseases |
| ASO          | Atherosclerosis |
| HUVECs       | Human umbilical vein endothelial cells |
| EC           | Endothelial cells |
| GSH          | Glutathione |
| COPD         | Chronic obstructive pulmonary disease |
| AECOPD       | Acute exacerbation of chronic obstructive pulmonary disease |
| MDA          | Malondialdehyde |
| GLU          | Glutamic acid |
| SOD          | Superoxide dismutase |
| HG           | High glucose |
| HCAECs       | Human coronary artery endothelial cells |
| OX-LDL       | Oxidised low-density lipoprotein |
| eNOS         | Endothelial nitric oxide synthase |
| LOX-1        | Low-density lipoprotein receptor 1 |
| LDH          | Lactate dehydrogenase |
| ICAM-1       | Intercellular adhesion molecule-1 |
| VCAM-1       | Vascular cell adhesion molecule-1 |
| FIB          | Fibrinogen |
| PT           | Prothrombin time |
| PAF          | Platelet-activating factor |
| PAI          | Plasminogen activator |
| t-PA         | Tissue plasminogen activator |
| AT-III       | Anti-thrombin III |
| MI/R         | Myocardial ischemia/reperfusion |
| MI           | Myocardial infarction |
| I/R          | Ischemia/reperfusion |
| A/R          | Hypoxia/reoxygenation |
| P13K/Akt/    | Phosphatidylinositol-3-kinase/protein |
| GSK3β        | kinase B/glycogen synthase kinase 3β |
| Ang II       | Angiotensin II |
| TXB2         | Thromboxane B2 |
| OGD          | Oxygen-glucose deprivation |
| BMECs        | Brain micro-vascular endothelial cells |
| AS-IV        | Astragaloside IV |
| CIRI         | Cerebral ischemia-reperfusion injury |
| CAT          | Catalase |
| NSE          | Neurone specific enolase |
| S-100B       | S-100B protein |
| MVD          | Micro-vessel density |
| CRE          | Creatinine |
| BUN          | Blood urea nitrogen |
| PRO          | Proline |
| Akt          | Protein kinase B |
| HKII         | Hexokinase |
| ROS          | Reactive oxygen species |
| Caspase-3    | Cysteine aspartic protease |
| Mst1         | Protein kinase MST |
| Cyt-c-       | Cytochrome C |
| HETE         | 15-hydroxyeicosatetraenoic acid |
| BBB          | Blood-brain barrier |
| mirna-1      | Micro-RNA-1 |
| TLR4         | Toll-like receptor 4 |
| NF-κB p65    | Nuclear transcription factor-κB |
| TNF-α        | Tumour necrosis factor-α |
| IL-6         | Interleukin-6 |
| MAPK         | Mitogen-activated protein kinase |
| ALI          | Acute lung injury |
| LPS          | Lipopolysaccharide |
| LDL-C        | Low-density lipoprotein |
| TG           | Triglyceride |
| TC           | Total cholesterol |
| HDL-C        | High-density lipoprotein |
| FASN         | Fatty acids synthase |
| PPAR-γ       | Peroxisome proliferator-activated receptor |
| SCD1         | Stearoyl-coadesaturase1 |
| Sirt1        | Silent information regulator1 |
| TN           | Triple-negative |
MMP2: Matrix metalloproteinase-2
EGF: Epidermal growth factor
HCC: Hepatocellular carcinoma
DN: Diabetic nephropathy
DM: Diabetes mellitus
WHO: World Health Organization
UAER: Urinary albumin excretion rate
DHI: Danhong injection
CS: Chitosan.

Data Availability
Data sharing is not applicable to this article as no data sets were generated or analysed during the current study.

Conflicts of Interest
The authors declare that they have no conflicts of interest or personal relationships that could have appeared to influence the work reported in this paper.

Authors’ Contributions
YC, XFX, and CP designed the study. YC drafted the manuscript. MFL, JYW, ZXD, and JRC were major contributors to reviewing the manuscript. XQP, GRC, LY, YLT, and GML drew the diagrams and the tables. Based on the contributions, YC was listed as the first author, while XFX and CP were the corresponding authors. All authors read and approved the final manuscript.

Acknowledgments
The authors would like to thank the National Science Foundation of China (NSFC), (grant numbers 81891012 and U19A2010), National Interdisciplinary Innovation Team of Traditional Chinese Medicine, (grant number ZYYCXTD-D-202209), and Natural Science Foundation of Sichuan Province (No.2022NSFSC0577). The authors would like to thank MogoEdit (https://www.mogoedit.com) for its English editing during the preparation of this manuscript.

References
[1] K. Yan, X. Wang, H. Zhu et al., “Safflower yellow improves insulin sensitivity in high-fat diet-induced obese mice by promoting peroxisome proliferator-activated receptor-γ2 expression in subcutaneous adipose tissue,” Journal of Diabetes Investigation, vol. 11, 2020.
[2] X. Wang, Y. Xu, C. Chu et al., “Effect of safflower yellow on early type II diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials,” Journal of Pediatric Endocrinology and Metabolism, vol. 32, no. 7, pp. 653–665, 2019.
[3] Y. P. Wang, Y. Guo, P. S. Wen et al., “Three ingredients of safflower alleviate acute lung injury and inhibit NET release induced by lipopolysaccharide,” Mediators of Inflammation, vol. 2020, Article ID 2720369, 12 pages, 2020.
[4] Q. Y. Lu, J. Q. Ma, Y. Y. Duan et al., “Carthamin yellow protects the heart against ischemia/reperfusion injury with reduced reactive oxygen species release and inflammatory response,” Journal of Cardiovascular Pharmacology, vol. 74, no. 74, pp. 228–234, 2019.
[5] Y. Liao, F. Liang, H. Liu et al., “Safflower yellow extract inhibits thrombus formation in mouse brain arteriole and exerts protective effects against hemorrhology disorders in a rat model of blood stasis syndrome,” Biotechnology & Biotechnological Equipment, vol. 32, no. 2, pp. 487–497, 2018.
[6] Z. Ma, C. Li, Y. Qiao et al., “Safflower yellow B suppresses HepG2 cell injury induced by oxidative stress through the AKT/Nrf2 pathway,” International Journal of Molecular Medicine, vol. 37, no. 3, pp. 603–612, 2016.
[7] X. J. Li, Y. Kang, R. R. Wang et al., “The effects of safflower yellow on acute exacerbation of chronic obstructive pulmonary disease: a randomized, controlled clinical trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2019, Article ID 5952742, 14 pages, 2019.
[8] M. R. Meselhy, S. Kadota, Y. Momose et al., “Two new quinonochalcone yellow pigments from Carthamus tinctorius and Ca2+ antagonistic activity of tinctormine,” Chemical and Pharmaceutical Bulletin, vol. 41, no. 10, pp. 1796–1802, 1993.
[9] J. Xuan, M. Huang, Y. Lu, and L. Tao, “Economic evaluation of safflower yellow injection for the treatment of patients with stable Angina pectoris in China: a cost-effectiveness analysis,” Journal of Alternative and Complementary Medicine (New York, NY), vol. 24, no. 6, pp. 564–569, 2018.
[10] X. Y. Wu, F. Y. Chen, X. R. Zhang, Y. G. Cen, and T. Y. Li, “Effects of Edaravone combined with Safflower yellow pigment on nerve function, blood lipid level and hemorheology in patients with acute cerebral infarction,” Prog Mod Bio, vol. 19, no. 05, pp. 919–923, 2019.
[11] Y. Ma, C. Feng, J. Wang et al., “Hydroxyl safflower yellow A regulates the tumor immune microenvironment to produce an anticancer effect in a mouse model of hepatocellular carcinoma,” Oncology Letters, vol. 17, no. 3, pp. 3503–3510, 2019.
[12] X. Z. Jin, L. Y. Shi, F. Chang, and Y. Lu, “Efficacy and safety of safflower yellow in early diabetic nephropathy: a meta-analysis,” Evidence-Based Complementary and Alternative Medicine (New York, NY), vol. 2019, Article ID 8065376, 10 pages, 2019.
[13] H. Zhu, X. Wang, H. Pan et al., “The mechanism by which safflower yellow decreases body fat mass and improves insulin sensitivity in HFD-induced obese mice,” Frontiers in Pharmacology, vol. 7, p. 127, 2016.
[14] Z. A. Xia, “Anti-oxidation of absorbed compound hydroxysafflolor yellow a analogous to traditional chinese medicine dan-chuan-hong following traumatic brain injury in rat,” Journal of Central South University, 2014.
[15] M. Jia, A Hydroxy Safflower Yellow Pigment by PI3K/Akt/Hexokinase II Way in H9c2 Cardiac Muscle Cells Induced by Hypoxia/reoxygenation Injury the Protection Mechanism in the Study, Hebei Medical University, Shijiazhuang, China, 2017.
[16] X. X. Wang, J. J. Wang, X. Wang et al., “Hydroxysafflilor yellow A inhibited abnormal proliferation of vascular endothelial cells,” Journal of Traditional Chinese Medical Sciences, vol. 39, no. 08, pp. 679–684, 2016.
[17] J. P. Wang, P. Wang, and R. H. Chen, “Effect of hydroxysafflilor yellow A on pro/anti-inflammatory cytokines in peripheral blood with sepsis in rats,” Journal of Sun Yat-sen University, vol. 38, no. 05, pp. 665–669, 2017.
[18] Q. Zhang, Y. R. Li, S. Zhang, B. B. Shen, and Z. Q. Zhang, “Protective effect of hydroxysafflilor yellowA on anoxia-
Evidence-Based Complementary and Alternative Medicine

roxygenation injury of myocardial cell by inhibiting the activation of Mst1,” *Journal of Wuzhou Chinese Medicine*, vol. 37, no. 03, pp. 270–275, 2017.

[19] Y. F. Xie, Y. Guo, S. D. Cao et al., “Hydroxysafflor yellow A attenuates hydrogen peroxide-induced oxidative damage on human umbilical vein endothelial cells,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 821428, 8 pages, 2020.

[20] T. J. Miao, L. Qian, F. Yu, L. G. Hu, J. Q. Han, and Y. An, “Protective effects of hydroxysafflor yellow an on high oxidized low density lipoprotein induced human coronary artery endothelial cells injuries,” *Cancer Cell Research*, vol. 6, no. 22, 2019.

[21] L. Tan, Y. Wang, Y. Jiang, R. Wang, J. Zu, and R. Tan, “Hydroxysafflor yellow A together with blood–brain barrier regulator lexiscan for cerebral ischemia reperfusion injury treatment,” *ACS Omega*, vol. 5, 2020.

[22] Y. Yang, C. Q. Shi, and J. Tong, “Agnostic effect of safollin A and its mechanism,” *Cent South Pharm*, vol. 17, no. 01, pp. 53–56, 2019.

[23] C.-C. Wang, C.-S. Choy, Y. H. Liu et al., “Protective effect of dried safflower petal aqueous extract and its main constituent, carthamus yellow, against lipopolysaccharide-induced inflammation in RAW264.7 macrophages,” *Journal of the Science of Food and Agriculture*, vol. 91, no. 2, pp. 218–225, 2011.

[24] X. Guo, M. Zheng, R. Pan et al., “Hydroxysafflor yellow A (HSYA) targets the platelet-activating factor (PAF) receptor and inhibits human bronchial smooth muscle activation induced by PAF,” *Food & Function*, vol. 10, no. 8, pp. 4661–4673, 2019.

[25] D. Zhou, Z. Qu, H. Wang et al., “The effect of hydroxysafflower yellow A on coronary heart disease through Bcl-2/Bax and PPAR-y,” *Experimental and Therapeutic Medicine*, vol. 15, no. 1, 2018.

[26] S.-y. Xi, Q. Zhang, C.-y. Liu, H. Xie, L.-f. Yue, and X.-m. Gao, “Effects of hydroxy safflower Yellow-A on tumor capillary angiogenesis in transplanted human gastric adenocarcinoma BGC-823 tumors in nude mice,” *Journal of Traditional Chinese Medicine*, vol. 32, no. 2, pp. 243–248, 2012.

[27] W. Y. Li, Y. T. Yu, and B. H. Yang, “Protective effect of hydroxysafflor yellow A against nonalcoholic fatty liver in high-fat diet induced rats by targeting Sirt1 signaling pathway,” *Cent South Pharm*, vol. 16, no. 11, pp. 1538–1542, 2018.

[28] X. D. Kong, S. F. Yuan, L. M. Pan, L. W. Zeng, M. Wu, and J. L. Shen, “The suppressive effect of carthamin yellow on the proliferation and Migration of human breast cancer cells and its related molecular mechanisms,” *Journal of Running Medical University*, vol. 39, no. 01, pp. 20–25, 2018.

[29] X. F. Wang, M. Jin, J. Tong, W. Wu, J. R. Li, and B. X. Zang, “Protective effect of hydroxyl Safflower yellow pigment A on acute lung injury induced by oleic acid-i lipopolysaccharide in rats,” *Chinese Journal of Pharmaceutical Science*, vol. 45, no. 7, pp. 940–944, 2010.

[30] H. F. Chen, Y. N. Ma, J. W. Chen, and J. Chen, “Safflower yellow up-regulates mi R-140-5p and influences IL-1β-induced autophagy, apoptosis and inflammatory factor secretion of osteoarthritides chondrocytes,” *Chinese Journal of Pharmaceuticalal*, vol. 37, no. 24, pp. 3350–3353, 2021.

[31] C. Wang, Y. Gao, Z. Zhang et al., “Safflower yellow alleviates osteoarthritis and prevents inflammation by inhibiting PGE2 release and regulating NF-κB/SIRT1/AMPK signaling pathways,” *Phytomedicine*, vol. 78, Article ID 155305, 2020.

[32] C. H. Wang and Y. C. An, “Mechanism study of safflor yellow affecting the biological characteristics of ovarian cancer SKOV-3 cells induced by TGF-B1 through reactive oxygen species,” *Chin Pharm*, vol. 24, no. 02, pp. 288–292, 2021.

[33] H. Zhang and J.-f. Zhang, “The application of connection number on generation system reliability assessment,” *Future Computing, Communication, Control and Management*, vol. 24, no. 05, pp. 715–721, 2012.

[34] S. Du, Y. Deng, H. Yuan, and Y. Sun, “Safflower yellow B Protects brain against cerebral ischemia reperfusion injury through AMPK/NE-κB pathway,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2019, Article ID 7219740, 11 pages, 2019.

[35] Y. Hu, Z. Gui, Y. Zhou, L. Xia, K. Lin, and Y. Xu, “Quercetin alleviates rat osteoarthritis by inhibiting inflammation and apoptosis of chondrocytes, modulating synovial macrophages polarization to M2 macrophages,” *Free Radical Biology & Medicine*, vol. 145, pp. 146–160, 2019.

[36] L. Xia, G. Jing, W. Yuan et al., “Inhibitive effect of endometrial carcinoma by Kaeppalol is interceded through apoptosis induction, G2/M phase cell cycle arrest, suppression of cell invasion and upregulation of m-TOR/PI3K signalling pathway,” *Journal of Buon*, vol. 24, no. 9, 2019.

[37] O. M. Zahad, Y. A. Samra and L. A. Issa, “P-Coumaric acid alleviates experimental diabetic nephropathy through modulation of Toll like receptor-4 in rats,” *Life Sciences*, vol. 238, Article ID 116965, 2019.

[38] T. Lee, H. S. Park, J. H. Jeong, and T. W. Jung, “Kynurenic acid attenuates pro-inflammatory reactions in lipopolysaccharide-stimulated endothelial cells through the PPARα/ HO-1-dependent pathway,” *Molecular and Cellular Endocrinology*, vol. 495, Article ID 110510, 2019.

[39] Y. Zhang, L. Yu, W. Jin et al., “Simultaneous optimization of the ultrasonic extraction method and determination of the antioxidant activities of hydroxysafflor yellow A and anhydrosafflor yellow B from safflower using a response surface methodology,” *Molecules (Basel, Switzerland)*, vol. 25, no. 5, 2020.

[40] F. Zhao, P. Wang, Y. Y. Jiao, X. X. Zhang, D. Q. Chen, and H. Y. Xu, “Hydroxysafflor yellow A: a systematic review on botanical resources, physicochemical properties, drug delivery system, pharmacokinetics, and pharmacological effects,” *Frontiers in Pharmacology*, vol. 11, 2020.

[41] X. Bai, W. X. Wang, R. J. Fu et al., “Therapeutic potential of hydroxysafflor yellow A on cardio-cerebrovascular diseases,” *Frontiers in Pharmacology*, vol. 11, 2020.

[42] X. Y. Xue, Y. Deng, J. Wang et al., “Hydroxysafflor yellow A, a natural compound from Carthamus tinctorius L with good effect of alleviating atherosclerosis,” *Phytochemistry*, vol. 91, 2021.

[43] Y. Li, J. P. Ge, Y. Y. Yin, X. M. Li, B. X. Zhao, and J. P. Gu, “Hydroxyl safflower yellow pigment A (HSYA) improves vascular endothelial injury induced by LPS: in vitro study,” *Latin American Journal of Pharmacy*, vol. 30, 2020.

[44] L. X. Cui, L. P. Sun, P. W. Zhao, X. Liu, D. N. Shi, and M. Chen, “Protective mechanism of hydroxysafflor yellow A on vascular endothelial cells injured by oxidative stress,” *Journal of Hunan University of Chinese Medicine*, vol. 39, no. 04, pp. 475–479, 2019.

[45] S. Chen, J. Ma, H. Zhu, S. Deng, M. Gu, and S. Qu, “Hydroxysafflor yellow A attenuates high glucose-induced human umbilical vein endothelial cell dysfunction,” *Human & Experimental Toxicology*, vol. 38, no. 6, pp. 685–693, 2019.
Evidence-Based Complementary and Alternative Medicine

[46] C. G. Duan, W. Zhang, and J. G. Wang, “Effect of safflower hydroxyl yellow A on the adhesion function of vascular endothelial cells,” China’s Naturopath, vol. 29, no. 15, pp. 92–94, 2021.

[47] P. H. Lu, C. Y. Kuo, C. C. Chan et al., “Safflower extract inhibits ADP-induced human platelet aggregation,” Plants (Basel, Switzerland), vol. 10, no. 6, 2021.

[48] L. W. Wang, X. Y. Cui, J. F. He et al., “Hydroxysafflor yellow A alleviates thrombosis and acetonophen-induced toxicity in vivo by enhancing blood circulation and poison excretion,” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, vol. 87, Article ID 153579, 2021.

[49] H. Xu, T. Liu, W. Wang et al., “Proteomic analysis of hydroxysafflor yellow A against cerebral ischemia/reperfusion injury in rats,” Rejuvenation Research, vol. 22, no. 6, pp. 503–512, 2019.

[50] Y. Y. Wang, “Effect of Safflower yellow pigment sodium chloride injection combined with low molecular weight heparin on perioperative coagulation fibrinolytic system and renal function of laparoscopic total hysterectomy,” Journal of Integrated Traditional and Western Medicine, vol. 27, no. 20, pp. 2192–2195, 2018.

[51] L. Diao, H. Li, S. M. Wang et al., “Observation on the effect of Safflower yellow pigment sodium chloride injection on preventing deep venous thrombosis in lower extremity after fracture,” Hebei Medical Journal, vol. 39, pp. 1706–1708, 2017.

[52] M. Zheng, R. Y. Pan, and B. X. Zang, “The inhibition of Hydroxysafflor yellow A on the platelet activating factor-induced bronchial asthma as sociated signal pathway,” Journal of Cardiovascular Pharmacology, vol. 36, pp. 408–408, 2018.

[53] H. N. Qi, J. Li, L. Wang, J. Q. He, J. J. Zhang, and W. Z. Wang, “Effects of carthamin yellow on cardiac function and levels of plasma cystatin C and high-sensitivity C reactive protein in elderly patients with chronic heart failure,” Guangxi Medical Journal, vol. 38, pp. 354–357, 2016.

[54] D. Zhou, T. Ding, B Ni, Y. Jing, and S Liu, “Hydroxysafflor Yellow A mitigated myocardial ischemia/reperfusion injury by inhibiting the activation of the JAK2/STAT1 pathway,” International Journal of Molecular Medicine, vol. 44, no. 2, pp. 405–416, 2019.

[55] J. Y. Cao, K. Wang, L. Lei et al., “Astragaloside and/or hydroxysafflor yellow A attenuates oxygen-glucose deprivation-induced cultured brain microvessel endothelial cell death through downregulation of PHLP-1,” Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 3597527, 12 pages, 2020.

[56] Y. Q. Zhao, Y. Q. Zhao, C. F. Chi, and B. Wang, “Cytotoxicity and antioxidant activity of protein hydrolysate of swim bladders of miiuy croaker against H2O2-mediated human umbilical...
Evidence-Based Complementary and Alternative Medicine

vein endothelial cell (HUVEC) injury," International Journal of Molecular Sciences, vol. 20, 2019.

[76] L. L. Wang, Y. F. Zhou, Y. C. Qin et al., "Methylthiopodopogonone B of Radix Ophiopogon protects cells from H2O2-induced apoptosis through the NADPH oxidase pathway in HUVECs," Molecular Medicine Reports, vol. 20, 2019.

[77] Z. X. Wang, Y. Wang, and J. Y. Lu, "GW26-e4587 IL-24 gene protects against H2O2-mediated injury of human umbilical vein endothelial cells and may be useful as a treatment for cardiovascular disease," Journal of the American College of Cardiology, 2015.

[78] S. L. Liu, H. R. Cai, Y. H. Chen et al., "Effects of Safflower yellow pigment on endothelial function, inflammatory response and oxidative stress in atherosclerotic rats," Chinese Journal of Gastroenterology, vol. 39, pp. 4585–4588, 2019.

[79] X. W. Yang, Y. H. Li, H. Zhang et al., "Safflower yellow regulates microglial polarization and inhibits inflammatory response in LPS-stimulated BV2 cells," International Journal of Immunopathology and Pharmacology, vol. 30, pp. 2508–2511, 2015.

[80] P. K. Fu, T. L. Pan, C. Y. Yang, K. C. Jeng, N. Y. Tang, and X. W. Yang, Y. H. Li, H. Zhang et al., "Safflower Yellow Injection Combined with Trimetazidine in the Treatment of Unstable Angina Pectoris and Its Effect on Blood Lipid and Atherosclerotic Plaque," Chinese Journal of Gastroenterology, vol. 38, pp. 5386–5388, 2018.

[81] J. F. Sheng, W. L. Yang, W. J. Xu, and H. T. Zhang, "Effect of Safflower yellow pigment combined with jinshuhua on serum lipid level and hemorheology in patients with primary nephrotic syndrome," Chin J Drug Use, vol. 15, pp. 5–7, 2018.

[82] O. Ciesielksi, M. Biesickierska, B. Panthu, V. Vialichka, L. Pirola, and A. Balcerczyk, "The epigenetic profile of tumor endothelial cells. Effects of combined therapy with antiangiogenic and epigenetic drugs on cancer progression," International Journal of Molecular Sciences, vol. 21, 2020.

[83] J. Wan, Y. Y. Feng, L. G. Du, V. P. Veeraraghavan, S. K. Mohan, and S. K. Guo, "Antiatherosclerotic activity of eriocitrin in high-fat-diet-induced atherosclerosis model rats," J Environ Toxic Cancer, vol. 39, 2020.

[84] W. J. Yin, Y. Q. Liang, and C. Qing, "Effect of hydroxysafflor yellow A and panax notoginseng saponins on the high risk factor for atherosclerosis and mechanism," Chin J Drug Eval, vol. 35, pp. 30–33, 2018.

[85] B. Bharat, B. Swati, P. Shrish et al., "Pharmacologic inhibition of epidermal growth factor receptor suppresses non-alcoholic fatty liver disease in murine fast-food diet model," Hepatology, vol. 70, 2019.

[86] J. Y. Li, J. Yu, X. S. Du, H. M. Zhang, B. Wang, and H. Guo, "Safflower polysaccharide induces NSCLC cell apoptosis by inhibition of the Akt pathway," Oncology Report, vol. 3, 2016.

[87] T. Gao, Y. D. Jiang, M. Li, and X. P. He, "Anti-tumor effect of hydroxysafflor yellow A on transplanted tumor of Lewis lung cancer rats," Journal of Cancer Research and Practice, vol. 15, pp. 461–464, 2016.

[88] Y. Cai, B. X. Zhao, Q. Y. Liang, Y. Q. Zhang, J. Y. Cai, and G. F. Li, "The selective effect of oflgycyrhrizin and glycyrrhetinic acid on topoisomerase IIA and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells," European Journal of Pharmacology, vol. 809, 2017.

[89] L. Luna-Dulceya, A. S. James, and R. C. Marcia, "SS16 promotes cell death by apoptosis through cell cycle arrest and inhibits migration and invasion of mda-mb-231 human breast cancer cells," Anti-Cancer Drugs, vol. 31, 2020.

[90] H. Fu, R. Wu, Y. Li et al., "Safflower yellow prevents pulmonary metastasis of breast cancer by inhibiting tumor cell invadopodia," The American Journal of Chinese Medicine, vol. 44, no. 7, pp. 1491–1506, 2016.

[91] Y. Liu, Q. Ouyang, Z. Sun et al., "The novel zinc finger protein 587B gene, ZNF587B, regulates cell proliferation and metastasis in ovarian cancer cells in vivo and in vitro," Cancer Management and Research, vol. 12, pp. 5119–5130, 2020.

[92] A. Y. Ali, L. Farrand, J. Y. Kim et al., "Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum," Annals of the New York Academy of Sciences, vol. 1271, 2012.

[93] Y. Fan, L. Wang, X. Han, X. Liu, and H. Ma, "Rab25 is responsible for phosphoinositide 3-kinase/AKT-mediated cisplatin resistance in human epithelial ovarian cancer cells," Cancer Management and Research, vol. 10, pp. 289–292, 2018.
Evidence-Based Complementary and Alternative Medicine

Molecular Medicine Reports, vol. 11, no. 3, pp. 2173–2178, 2015.

[105] R. J. Liang, J. L. Ying, and L. Zhu, "Effect of hydroxy-yellow pigment A from safflower on PI3K/Akt signaling pathway in ovarian cancer cell," Zhejiang J Integra Tradit Chin West Med, vol. 29, pp. 354–356, 2019.

[106] J. J. Wang, J. H. Hu, X. Yu et al., "Effects of Hydroxy Saffil or yellow A on the cell proliferation, apoptosis and cycle of cultured human gastric cancer cell," Chin J Tradit Chin Med Pharm, vol. 31, pp. 3738–3741, 2016.

[107] T. Issar, R. Arnold, N. C. G. Kwai et al., "Relative contributions of diabetes and chronic kidney disease to neuropathy development in diabetic nephropathy patients," Clinical Neurophysiology, vol. 130, no. 11, pp. 2088–2095, 2019.

[108] J. J. Liu, L. L. Hu, F. Hu, and H. Yuan, "Effect of Safflower yellow pigment on insulin resistance and blood hypercoagulability in patients with early type 2 diabetic nephropathy," Chin J Difficult Complicated Cases, vol. 8, pp. 805–808, 2018.

[109] Y. Zhao, Mechanisms of Hydroxysafflor Yellow A Improves Oxidative Stress Induced Bythyl Alcohol in Pancreatic β-cells, Shandong University, Jinan, China, 2019.

[110] X. Tong, J. Yang, Y. Zhao et al., "Greener extraction process and enhanced in vivo bioavailability of bioactive components from Carthamus tinctorius L. by natural deep eutectic solvents," Food Chemistry, vol. 348, Article ID 129090, 2021.

[111] B. Zhao, S. Gu, Y. Du, M. Shen, X. Liu, and Y. Shen, "Solid lipid nanoparticles as carriers for oral delivery of hydroxysafflor yellow A," International Journal of Pharmaceutics, vol. 535, no. 1-2, pp. 164–171, 2018.

[112] C.-Y. Li, J.-G. Yin, J. Zhang et al., "Pharmacokinetic profiles of hydroxysafflor yellow A following intravenous administration of its pure preparations in healthy Chinese volunteers," Journal of Ethnopharmacology, vol. 162, pp. 225–230, 2015.

[113] R. Yao, Y. Cao, R. Jiang, X. Zhang, F. Li, and S. Wang, "Pharmacokinetic characteristics of hydroxysafflor yellow A in normal and diabetic cardiomyopathy mice," Biomedical Chromatography: BMC, vol. 35, no. 10, Article ID e5173, 2021.

[114] M. L. Huang, H. P. Song, H. Q. Pang, W. Gao, and X. D. Wen, "Research progress of the pharmacokinetics of safflor yellow pigments," Pharmaceutical and Clinical Research, vol. 26, no. 04, pp. 287–290, 2020.

[115] C. Sheng, W. Peng, Z. Xia, and Y. Wang, "Plasma and cerebrospinal fluid pharmacokinetics of hydroxysafflor yellow A in patients with traumatic brain injury after intravenous administration of Xuebijing using LC-MS/MS method," Xenobiotica, vol. 50, no. 5, pp. 545–551, 2020.

[116] Y. Jin, L. Wu, Y. Tang et al., "UFLC-Q-TOF/MS based screening and identification of the metabolites in plasma, bile, urine and feces of normal and blood stasis rats after oral administration of hydroxysafflor yellow A," Journal of Chromatography B, vol. 1012-1013, pp. 124–129, 2016.

[117] L. Wu, Y. Tang, C. Shan et al., "A comprehensive in vitro and in vivo metabolism study of hydroxysafflor yellow A," Journal of Mass Spectrometry, vol. 53, no. 2, pp. 99–108, 2018.

[118] P. Jia, S. Wang, X. Meng et al., "Effects of ionic liquid and nanogold particles on high-performance liquid chromatography-electrochemical detection and their application in highly efficient separation and sensitive analysis of five phenolic acids in Xuebijing injection," Talanta, vol. 107, pp. 103–110, 2013.

[119] M. Jiang, L. Y. Zhou, N. Xu, and Q. An, "Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways," Thoracic Cancer, vol. 10, no. 6, pp. 1319–1333, 2019.

[120] Z. Q. Wang and Z. L. Ding, "Progress in clinical application of Safflower yellow pigment," Chin Pharmind, vol. 23, no. 16, pp. 125–127, 2014.

[121] Z. H. Wu, "Overview of the research progress of traditional Chinese medicine safflower," W L Med Inf Digest, vol. 19, no. 34, pp. 33–34, 2019.

[122] S. J. Liu, Z. S. Tang, C. L. Cui et al., "Progress in the study of chemical constituents of traditional Chinese medicine safflower," Henan J Tradit Chin Med, vol. 37, no. 01, pp. 168–171, 2017.

[123] Y. L. Hu, J. Y. Luo, S. R. Hu, H. Fu, S. H. Yang, and M. H. Yang, "Application of natural plant pigments in enlarged health industry," Chin J Chin Mater Med, vol. 42, no. 13, pp. 2433–2438, 2017.

[124] J. F. Yang, R. Wang, X. H. Cheng et al., "The vascular dilatation induced by Hydroxysafflor yellow A (HSYA) on rat mesenteric artery through TRPV4-dependent calcium influx in endothelial cells," Journal of Ethnopharmacology, vol. 256, 2020.

[125] N. Wang, D. M. He, Y. Q. Zhou et al., "Hydroxysafflor yellow A actives BK Ca channels and inhibits L-type Ca channels to induce vascular relaxation," European Journal of Pharmacology, vol. 870, 2020.

[126] S. Y. Lee, S. S. Cho, C. S. Bae, M. S. Bae, and D. H. Park, "Socheongryongtang suppresses COPD-related changes in the pulmonary system through both cytokines and chemokines in a LPS COPD model," Pharmaceutical Biology, vol. 58, no. 1, pp. 538–544, 2020.

[127] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[128] X. L. Wu, "Efficacy enhancing effect of Shikonin on human liver cancer HepG2 cells treated by Cisplatin," J Chin Med J Res Prac, vol. 31, pp. 35–38, 2017.

[129] Y. Wu and R. Liu, "Study on the drug-resistant reversal effects of ginsenoside R h2 in human hepatocellular carcinoma Hep G2/ADM cells and its mechanism," J Med Postgr, vol. 30, pp. 476–480, 2017.

[130] N. U. Khan, J. Lin, X. K. Liu et al., "Insights into predicting diabetic nephropathy using urinary biomarkers," BBA—Proteins and Proteomics, vol. 1868, no. 10, 2020.

[131] X. Feng, Y. Li, Y. Wang et al., "Danhong injection in cardiovascular and cerebrovascular diseases: pharmacological actions, molecular mechanisms, and therapeutic potential," Pharmacological Research, vol. 139, pp. 62–75, 2019.

[132] M. Zhou, P. Ren, S. Li et al., "Danhong injection attenuates high-fat–induced atherosclerosis and macrophage lipid accumulation by regulating the PI3K/AKT insulin pathway," Journal of Cardiovascular Pharmacology, vol. 74, 2019.

[133] J. O. Orgah, S. He, Y. Wang et al., "Pharmacological potential of the combination of Salvia miltiorrhiza (Danshen) and Carthamus tinctorius (Honghua) for diabetes mellitus and its cardiovascular complications," Pharmacological Research, vol. 153, Article ID 104654, 2020.

[134] D. Q. Zhang, Y. P. Mu, Y. Xu, J. M. Chen, P. Liu, and W. Liu, "Research progress in Chinese medicine preparations for promoting blood circulation and removing blood stasis for..."
cirrhotic patients with portal vein thrombosis following splenectomy,” Chin J Inte Med, 2020.

[135] Y. Guo, J. H. Yang, S. D. Cao et al., “Effect of main ingredients of Danhong Injection against oxidative stress induced autophagy injury via miR-19a/SIRT1 pathway in endothelial cells,” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, vol. 83, Article ID 153480, 2021.

[136] Z. W. Gu, “Analysis on the clinical effect of Safflower yellow injection combined with western medicine in the treatment of unstable angina pectoris,” Sys Med, vol. 4, no. 04, pp. 15–17, 2019.

[137] X. L. Liao, K. H. Xin, Z. Min, T. Chen, and X. Wu, “Effect of Safflower yellow injection on unstable angina pectoris,” Contemp Med, vol. 25, no. 33, pp. 164–166, 2019.

[138] J. S. Ruan, L. Peng, B. Zheng, and J. Y. He, “Curative effect analysis of metoprolol combined with safflower yellow injection in the treatment of unstable angina pectoris,” Med J West Chin, vol. 31, no. 10, pp. 1601–1604, 2019.

[139] L. P. Shi, X. Q. Du, Y. J. Li, H. Cao, M. H. Liu, and D. Q. Yang, “Effect of honghua yellow injection on hemorheology and efficacy of unstable angina pectoris,” Clin Res Tradict Chin Med, vol. 9, no. 32, pp. 17–19, 2017.

[140] Z. Zhou, “Effect of Safflower yellow sodium chloride injection combined with metoprolol tartrate on electrocardiogram and serum McP-1 and mmp-9 levels in patients with unstable angina pectoris,” Medicine, vol. 40, no. 02, pp. 147–149, 2019.

[141] B. L. Wang, Y. Wan, D. J. Zhang, S. Li, and C. Y. Guo, “Preparation of taohong siwu granules and its anti-platelet aggregation effect,” Lishizhen Med Mater Med Res, vol. 30, no. 04, pp. 881–885, 2019.

[142] B. L. Wang, Preparation of Taohong Siwu Decoction and Granules and Their Anti-platelet Aggregation Effect, Hebei North University, Zhangjiakou, China, 2018.

[143] H. Li, G. R. Shi, A. Z. Xu, H. Zhang, J. Wu, and Y. Zhang, “Study on the quality standard of bitong granules,” Baotou Med Univ, vol. 34, no. 12, pp. 109–112, 2018.

[144] A. Z. Xu, H. Li, H. Zhang, Y. Zhang, G. R. Shi, and M. An, “Content determination of hydroxyasafflor yellow A and puerarin in bitong granules,” Eval Anal Drug-Tuse Hos Chin, vol. 19, no. 06, pp. 721–723, 2019.

[145] D. D. Li, S. C. Guo, S. Z. Kong, F. J. Chen, S. D. Li, and J. C. Li, “A study on preparation of hydroxyasafflor yellow A—chitosan microspheres,” Guangdong Ocean Univ, vol. 37, no. 03, pp. 73–79, 2017.